Viveve Medical (NASDAQ:VIVE) Stock Price Up 85.3%

Viveve Medical Inc (NASDAQ:VIVE)’s share price rose 85.3% during trading on Wednesday . The company traded as high as $3.82 and last traded at $7.04, approximately 877,453 shares were traded during mid-day trading. A decline of 4% from the average daily volume of 913,140 shares. The stock had previously closed at $3.80.

VIVE has been the subject of a number of research reports. ValuEngine raised Viveve Medical from a “hold” rating to a “buy” rating in a research note on Wednesday, October 2nd. Maxim Group reaffirmed a “hold” rating on shares of Viveve Medical in a research report on Friday, August 9th. LADENBURG THALM/SH SH cut Viveve Medical from a “buy” rating to a “neutral” rating in a research report on Wednesday, July 24th. Stifel Nicolaus cut Viveve Medical from a “buy” rating to a “hold” rating and cut their target price for the company from $3.00 to $1.00 in a research report on Monday, July 22nd. Finally, Mizuho cut Viveve Medical from a “buy” rating to an “underperform” rating and cut their target price for the company from $4.00 to $0.20 in a research report on Tuesday, July 23rd. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and one has given a buy rating to the company’s stock. Viveve Medical currently has a consensus rating of “Hold” and an average target price of $2.24.

The company has a market cap of $1.51 million, a PE ratio of -0.03 and a beta of 0.02. The company has a 50-day moving average of $2.50 and a 200-day moving average of $0.95.

Viveve Medical (NASDAQ:VIVE) last announced its earnings results on Thursday, August 8th. The company reported ($21.00) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($18.00) by ($3.00). The company had revenue of $1.05 million for the quarter, compared to analysts’ expectations of $3.92 million. Viveve Medical had a negative net margin of 341.01% and a negative return on equity of 2,976.15%. As a group, equities analysts predict that Viveve Medical Inc will post -69 EPS for the current fiscal year.

In related news, major shareholder Goldman Sachs Group Inc sold 92,425 shares of Viveve Medical stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $4.81, for a total transaction of $444,564.25. 5.20% of the stock is owned by insiders.

Viveve Medical Company Profile (NASDAQ:VIVE)

Viveve Medical, Inc designs, develops, manufactures, and markets medical devices for the non-invasive treatment of various post-partum conditions. The company offers Viveve System, a radio frequency generator, a reusable hand piece, and single-use treatment tip, as well as other consumable components.

Further Reading: What is the NASDAQ Stock Market?

Receive News & Ratings for Viveve Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical and related companies with's FREE daily email newsletter.